Geode Capital Management, LLC Metacrine, Inc. Transaction History

Geode Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$0.36 - $0.63 $9,882 - $17,294	27,451 Added 56.27%	76,235 $38,000
Q1 2022 May 13, 2022	BUY	$0.43 - $0.7 $3,704 - $6,031	8,616 Added 21.45%	48,784 $29,000
Q4 2021 Feb 11, 2022	BUY	$0.64 - $3.83 $12,707 - $76,048	19,856 Added 97.76%	40,168 $27,000
Q3 2021 Nov 12, 2021	SELL	$2.61 - $3.84 $20,728 - $30,497	-7,942 Reduced 28.11%	20,312 $69,000
Q2 2021 Aug 13, 2021	SELL	$3.37 - $5.73 $102,609 - $174,467	-30,448 Reduced 51.87%	28,254 $107,000

Q1 2021 May 12, 2021	BUY	$6.2 - $11.0 $67,741 - $120,186	10,926 Added 22.87%	58,702 $363,000
Q4 2020 Feb 12, 2021	BUY	$7.75 - $11.42 $370,264 - $545,601	47,776 New	47,776 $375,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.